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INTRODUCTION
Allergen immunotherapy is the only treatment that can change 
the natural course of allergic diseases. Immunotherapy can be 
a curative treatment for allergic rhinitis or asthma.1 The treat-
ment improves symptom scores, decreases medication costs, 
and may prevent additional sensitization and progression to 
asthma.2,3 In addition, research data on the effectiveness of im-
munotherapy for atopic dermatitis is increasing.4-6 
The efficacy of immunotherapy is usually determined by 
clinical outcomes and laboratory findings: specific immuno-
globulin G4 (sIgG4), specific immunoglobulin E (sIgE), sIgE/
sIgG4 ratio, and IgE-blocking factors. Although the mechanisms 
are not fully understood, studies support the production of 
blocking antibodies, such as sIgG4, as one of the key mecha-
nisms of immunotherapy.7,8 Upon initiation of immunotherapy, 
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Key Words:  Blocking factor, house dust mite, IgG4, immunotherapy, specific IgE
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: March 18, 2016   Revised: May 13, 2016
Accepted: May 15, 2016
Corresponding author: Dr. Jung-Won Park, Division of Allergy and Immunology, 
Department of Internal Medicine, Yonsei University College of Medicine, 50-1 
Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-1961, Fax: 82-2-393-6884, E-mail: parkjw@yuhs.ac
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2016 Nov;57(6):1427-1434
http://dx.doi.org/10.3349/ymj.2016.57.6.1427
1428
Comparison of Commercial Subcutaneous Immunotherapy
http://dx.doi.org/10.3349/ymj.2016.57.6.1427
regulatory T cells cause B cells to produce sIgG4 instead of sIgE. 
As a result, IgE-mediated allergic reactions are inhibited by 
competitive binding of IgG4 against the allergen. As a short term 
effect, IgG4 starts to increase after one week and continues to 
increase for up to 1–3 years after treatment.8 As compared to 
IgG4, IgE levels increases from one week to 6 months after treat-
ment and decrease thereafter.8 IgE-blocking factor, which blocks 
allergen-sIgE binding, are also known as marker for immuno-
therapy outcomes.9,10 Therefore, IgE and IgE/IgG4 ratio de-
crease, whereas IgG4 increases, as a long term effect of immu-
notherapy.11
Immunotherapy comprises subcutaneous and sublingual im-
munotherapy. Subcutaneous immunotherapy (SCIT) is clas-
sified into two main types of prescription patterns: American 
and European styles.2,12 There are some differences in Europe-
an and American SCIT, yet both are available in Korea. Specif-
ically, when preparing house dust mite (HDM) SCIT reagent, 
the European style allows both the mite bodies and feces for the 
source materials, whereas American style only allows purified 
mite bodies. Since the allergen extraction and standardization 
methods are different between these styles, potency units, 
which demonstrate allergenicity, may differ from company to 
company. These differences in allergenicity might result in 
different short-term or long term effects of immunotherapy. 
Although source materials and preparation methods are 
different between manufacturers,12 to our knowledge, there is 
no research that has compared the immunological changes in-
duced by commercial SCIT reagents. The purpose of this study 
was to compare the immunological potency of three com-
mercial HDM SCIT reagents in terms of sIgG4, sIgE, and aller-
gen blocking factor levels. Additionally, in order to compare 
the differences in American and European styles, the Hollis-
ter-Stier® (Spokane, WA, USA) product was chosen as a repre-
sentative of American style and both Tyrosine S® (Allergy Ther-
apeutics, Worthing, UK) and Novo-Helisen® (Allergopharma, 
Reinbek, Germany) were chosen to represent European style. 
MATERIALS AND METHODS
Subjects
The enrollment was retrospectively accomplished at the Aller-
gy and Asthma Center at Severance Hospital in Seoul, Korea. 
Specialized allergists, dermatologist, and pediatricians work 
at this center. HDM sensitized patients who were receiving 
SCIT with three different kinds of reagents were enrolled from 
2013 to 2014. Patients whose therapeutic dose had reached a 
maintenance dose and those without any side effects were se-
lected. HDM sensitization was confirmed by a skin prick test 
or detection of specific IgE to Dermatophagoides farinae (D. 
farinae) and Dermatophagoides pteronyssinus (D. pteronyssi-
nus). HDM sensitized patients who were not receiving any 
immunotherapy were selected as a control group. All the par-
ticipants provided written informed consent. The Institutional 
Review Board of the Yonsei University Health System ap-
proved this study (No. 4-2013-0397). Sera obtained before and 
after the SCIT were stored at -70°C. 
HDM SCIT reagents
Three kinds of commercially available HDM SCIT reagents 
were compared: 1) aluminum hydroxide adsorbed Novo-
Helisen® depot, 2) Hollister-Stier® aqueous extract, and 3) L-ty-
rosine adsorbed Tyrosine S®. The three different immunothera-
py reagents use independent allergen units. Novo-Helisen® 
depot is standardized in Therapeutic units (TU), Hollister-Stier® 
is standardized in Allergy units (AU), and Tyrosine S® is stan-
dardized in TU. Information on these SCIT reagents is shown 
in Table 1. 
 
Dermatophagoides farinae sIgE and sIgG4 
measurement
We measured serum sIgE and sIgG4 to D. farinae using the 
ImmunoCAP® system (ThermoFisher Scientific, Uppsala, Swe-
den). This measurement system has a detection range from 
0.1 kUA/L to 100 kUA/L for sIgE. IgE titers higher than 0.35 
kUA/L were designated as positive. For sIgG4, the detection 
Table 1. Comparison of Three Types of HDM SCIT Reagents
Hollister-Stier®
(maintenance course)
Novo-Helisen®
(strength 3, red bottle)
Tyrosine S®
(maintenance course, red bottle)
Manufacturer Hollister-Stier (USA) Allergopharma (Germany) Allergy Therapeutics (UK)
Extract preparation Aqueous allergen extract Aluminum hydroxide adsorbed extract L-tyrosine adsorbed extract
Potency units AU TU TU
Active constituents D.p:D.f=50:50 D.p:D.f=50:50 D.p:D.f=50:50
Other constituents Glycerin, 0.4% phenol, 0.03% HSA, 
  0.9% NaCl
Aluminum hydroxide, phenol, NaCl, NaHCO3, 
  water for injection
L-Tyrosine, glycerol (only for certain allergen 
  combinations), phenol, NaCl, buffer salts 
  (disodium phosphate dodecahydrate, sodium 
  dihydrogen phosphate dehydrate), water 
  for injection
AU, Allergy unit; TU, Therapeutic unit; D.p, Dermatophagoides pteronyssinus; D.f, Dermatophagoides farinae; HDM, house dust mite; HSA, human serum albu-
min; SCIT, subcutaneous immunotherapy.
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range was 0.07 mg/L to 30 mg/L.
IgE and IgG4 immunoblot using Dermatophagoides 
farinae
D. farinae protein extract was separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 
a 15% gel. Standardized D. farinae protein extract was kindly 
provided by the Yonsei Allergy Institute.13 Separated proteins 
were transferred to polyvinylidene difluoride membranes (0.45 
μm, GE Water & Process Technologies, Trevose, PA, USA) to re-
act with three groups of patient sera (five randomly chosen pa-
tients from each group). For inhibition of non-specific binding, 
the membranes were incubated in 3% skim milk overnight be-
fore overnight sera incubation at 37°C. As a secondary anti-
body, 1:1000 diluted mouse anti-human IgE and IgG4 (South-
ern Biotech, Birmingham, AL, USA) were incubated for 1 hour. 
Nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl-phos-
phate (Promega, Madison, WI, USA) were used for color de-
velopment. 
IgE blocking factor assay
The blocking factor that can inhibit IgE-binding to D. farinae 
extract was also measured before and after immunotherapy.14 
Anti-human IgE antibodies (Sigma-Aldrich, St. Louise, MO, 
USA, 5 µg/mL) were coated onto a 96-well microplate and kept 
at 4°C overnight. After washing with phosphate-buffered sa-
line containing 0.05% Tween 20 (PBST), the plate was incubat-
ed for 1 hour in 3% skim milk. The plates were washed with 
PBST, and patient sera (non-diluted, 50 μL/well, 1 hour) were 
then added. In order to detect the blocking factor that inhibits 
IgE binding, the experimental groups were divided into two: 
wash or no-wash. The experimental procedures were identical 
in those two groups except that in the no-wash group, the wash 
step was omitted after the addition of patient sera. Consequ-
ently, in the no-wash group, blocking factors left in the sera 
would inhibit the IgE binding of D. farinae extract. Subse-
quently, biotinylated D. farinae extract was added as an anti-
gen (10 µg/mL, 1 hour). After washing with PBST three times, 
horseradish peroxidase conjugated streptavidin (Sigma-Al-
drich, St. Louise, MO, USA) was used at a 1:1000 dilution, and 
then 3,3',5,5'-Tetramethylbenzidine (Kirkegaard & Perry Lab-
oratories, Gaithersburg, MD, USA) was added for color devel-
opment. The color development was stopped with sulfuric acid 
and the optical density (OD) was measured at 450 nm. The 
blocking factor index was calculated using the following for-
mula: blocking factor index=1-(ODno wash/ODwash). Blocking 
factor index was used for measuring the levels of blocking fac-
tors of the three SCIT groups. 
Statistical analysis
The data were analyzed using SPSS 18.0 (SPSS Inc., Chicago, 
IL, USA). For comparison of demographic parameters, Kruskal-
Wallis test and Fisher’s exact test were used. Dunn’s test was 
performed after Kruskal-Wallis test for multiple comparisons 
between the four groups. To analyze sIgE, sIgG4, and the block-
ing factor before and after SCIT, the Wilcoxon signed rank test 
and repeated-measured ANOVA test were used. 
RESULTS
Baseline characteristics
Demographics of the enrolled patients are shown in Table 2. 
Mean age was 30.1 years old. Males composed 45.8% of the 
population. Regarding age and sex, there were no significant 
differences between the three groups. Of the clinical diagno-
ses, 33% of patients had asthma, 67% had allergic rhinitis, and 
29% had atopic dermatitis. Excluding the control patients, 72.2% 
of atopic dermatitis patients were treated with Tyrosine S® 
(p<0.001), and 72.2% of allergic rhinitis patients were treated 
Table 2. Baseline Characteristics of the Patients
Total
(n=72)
Hollister-Stier®
(n=19)
Tyrosine S®
(n=16)
Novo-Helisen®
(n=10)
Control
(n=27)
p value
Age (yr) 30.1±10.8 31.1±11.3 26.5±10.6 29.4±12.2 31.8±10.0 0.397
Sex (M:F) 33:39 8:11 8:8 4:6 13:14 0.936
Asthma, n (%) 26 (36.1) 9 (47.4) 4 (25.0) 4 (40.0) 9 (33.3) 0.552
Allergic rhinitis, n (%) 53 (73.6) 19 (100.0) 3 (18.8) 8 (80.0) 23 (85.2) <0.001
Atopic dermatitis, n (%) 23 (31.9) 2 (10.5) 13 (81.3) 3 (30.0) 5 (18.5) <0.001
Pre IT sIgE to D.f (kUA/L) 44.6±37.6 36.7±27.8 75.1±36.5 58.9±36.7 26.8±32.5 0.001
Pre IT sIgG4 to D.f (mg/L) 0.4±0.5 0.3±0.2 0.4±0.2 0.6±0.8 0.4±0.6  0.112
Post IT sIgE to D.f (kUA/L) 61.8±38.0 50.1±39.8 77.3±33.4 56.7±36.6 NA 0.194
Post IT sIgG4 to D.f (mg/L) 2.3±3.1 3.7±4.1 0.7±0.5 2.2±2.3 NA <0.001
IT duration (months) 13.9±6.6 15.2±6.7 12.8±3.6 13.4±9.7 NA 0.362
IT maintenance dose,
  mean (range)
761.8 AU
(432–1600 AU)
14999.4 TU
(6666.4–16666 TU)
3057.1 TU
(1600–5000 TU)
NA NA
AU, Allergy unit; D.f, Dermatophagoides farinae; IT, immunotherapy; NA, not available; TU, Therapeutic unit; sIgE, specific immunoglobulin E.
p value was calculated by Kruskal-Wallis test, Fisher’s exact test.
1430
Comparison of Commercial Subcutaneous Immunotherapy
http://dx.doi.org/10.3349/ymj.2016.57.6.1427
with Hollister-Stier® or Novo-Helisen®. All the participants de-
monstrated more than 90% compliance to SCIT.
SCIT duration was not significantly different between the 
groups. Mean maintenance dose of IT in the Hollister-Stier® 
group was 761.8 AU, which satisfied the recommended dose 
range (500–2000 AU).15 Tyrosine S® group patients received an 
average of 14999 TU as a maintenance dose, and the Novo-
Helisen® group received an average of 3057 TU.
Changes of sIgE levels after SCIT using ImmunoCAP 
method
We first compared the immunologic parameters before and 
after SCIT. Before treatment, sIgE levels to D. farinae were two 
times higher in the Tyrosine S® group (75.1±36.5 kUA/L) than 
the Hollister-Stier® group (36.7±27.8 kUA/L) (p=0.001). How-
ever, after SCIT, the differences in sIgE levels to D. farinae dis-
appeared (p=0.194). Specific IgE levels to D. farinae were not 
different between the groups before and after treatment. No-
vo-Helisen® group showed a slight decrease in sIgE levels to D. 
farinae, but did not show statistical significance. Results of 
sIgE are shown in Fig. 1A. 
Next, we specifically investigated sIgE levels to the compo-
nent allergen, Der p2. Before SCIT, it showed the same pattern 
with D. farinae. The Tyrosine S® group was the highest, fol-
lowed by Novo-Helisen® and Hollister-Stier® in order. However, 
sIgE to Der p 2 after SCIT was different from sIgE to D. farinae. 
Fig. 1. Comparison of immunologic parameters before and after immuno-
therapy. Dermatophagoides farinae-specific IgE titers (A), specific IgG4 
titers (B), specific IgE/IgG4 ratio (C), before and after immunotherapy. 
Data represent the mean±standard error of the mean. *p value<0.05, †p 
value<0.005. IT, immunotherapy; IgE, immunoglobulin E; IgG4, immuno-
globulin G4.
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Changes of sIgG4 levels after SCIT using ImmunoCAP 
method
Contrary to the sIgE pattern, initial sIgG4 levels to D. farinae 
were not different between the groups (p=0.112). After an av-
erage of 13.9 months of SCIT, sIgG4 levels to D. farinae incr-
eased in all three IT groups (Fig. 1B). The change was highest 
in the Hollister-Stier® group: 19.6 fold (p<0.001), followed by 
Novo-Helisen® and Tyrosine S®. The IgE/IgG4 ratio showed 
similar patterns with sIgG4 levels to D. farinae (Fig. 1C). All 
three groups had a decreased ratio of IgE/IgG4, although the 
degree of decline was highest in the Hollister-Stier® group 
(p=0.001) (Fig. 1C). 
Changes of blocking factor index after SCIT
As mentioned above, blocking factor was checked using the 
enzyme-linked immunosorbent assay (ELISA) method. A sche-
matic picture of the blocking factor assay is shown in Fig. 2A. 
The closer blocking factor index reaches to 1, the higher the 
blocking factors are produced. The Hollister-Stier® group showed 
significant increases therein after SCIT, compared to baseline 
(p=0.009) (Fig. 2B). Changes in the other groups were statisti-
cally insignificant. 
 
Changes of sIgE and sIgG4 levels after SCIT using 
immunoblot 
Immunologic responses to major component allergens were 
also analyzed using immunoblot. Group 2 major allergen (Der f 
2) migrates to the 14 kDa band on SDS-PAGE. Immunoblot to 
detect sIgE against Der f 2 is shown in Fig. 3. Although sIgE ti-
ters to D. farinae were not significantly changed in the Hollis-
ter-Stier® group (Fig. 1A), Patients H1, H2, H4, and H5 showed 
decreased IgE reactivity to Der f 2 (Fig. 3A). However, it was not 
different before and after SCIT in the Tyrosine S® and Novo-
Helisen® groups (Fig. 3B and C). Next, we tried to detect sIgE to 
major component allergen using ImmunoCAP. However, since 
Der f 2 sIgE is not commercially available from ImmunoCAP, 
the Der p 2 sIgE was measured instead (Fig. 3D). Der p 2 sIgE 
levels were decreased in Patients H1, H3, and H5. Note that in 
Patient H3, the sIgE levels to D. farinae were above the upper 
detection limit (>100 kUA/L) both before and after SCIT. How-
ever, Der p 2 decreased from 46.6 to 35.9 kUA/L. In Patient H5, 
sIgE levels to D. farinae were the same before and after SCIT 
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(both 21.1 kUA/L). However, the Der p 2 sIgE level reduced by 
half (6.3 to 3.5 kUA/L).
Specific IgG4 immunoblot is shown at Fig. 4. In the Hollister-
Stier® group, three out of five patents (Patients 1, 4, and 5) sh-
owed increased signal intensity at the 14 kDa band (Fig. 4A). 
The Tyrosine S® group showed a relatively slight increase of 
band signal, compared with the Hollister-Stier® group (Fig. 4B). 
Specific IgG4 level and blocking factor index of the five patients 
are demonstrated in Fig. 4D and E respectively.
DISCUSSION
Comparing the efficacy of HDM SCIT reagents manufactured 
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by different companies are difficult. First, manufacturers adopt 
their own allergen potency units that make it hard for clinicians 
to directly compare their potency.16 Hollister-Stier® expresses 
allergy potency as AU. Meanwhile, Tyrosine S® and Novo-He-
lisen® both express allergy potency as TU, although the mean-
ings thereof are different. Tyrosine S® TU is derived from opti-
mal diagnostic concentration of the skin prick test, and Novo-
Helisen® TU in comparison is derived from an in-house refer-
ence preparation and clinical efficacy.17 Second, source mate-
rials are different among SCIT reagent manufacturers due to 
legislations. For instance, in the USA, pure mite bodies are re-
quired by the United States Food and Drug Administration, 
whereas in the European Medicines Agency allows mite bod-
ies and feces.18 Furthermore, SCIT preparation methods are 
different for each company. For a more potent vaccine, alumi-
num hydroxide or L-tyrosine can be adsorbed in the HDM ex-
tract. For these reasons, it is not meaningful to compare in vi-
tro parameters for evaluating the efficacy of different SCIT 
products. 
Results of this study are important since reagents were com-
pared head to head with clinically applicable immunological 
parameters. In this study, we compared immunological pa-
rameters before and after the SCIT treatment. Different sIgG4 
responses from each of the SCIT reagents were observed. The 
Hollister-Stier® reagent induced the highest increase of sIgG4 
and blocking factor, followed by Novo-Helisen® and Tyrosine-
S®. Considering that the immunotherapy continues for 3 to 5 
years, the duration of this study suggests early changes of im-
munotherapy. That is, Hollister-Stier SCIT reagents may exert 
a faster therapeutic effect. Although sIgE levels to D. farinae 
increased in Hollister-Stier group, the decrease of sIgE levels to 
component allergens, Der p 2 (statistically insignificant) and 
Der f 2, were confirmed by ImmunoCAP and immunoblot, re-
spectively. This phenomenon could mean that Der p 2, rather 
than total extract, could reflect the inhibited IgE binding activ-
ity to HDM. Therefore, further study will be needed to delin-
eate the relationship. 
Discordance between IgE reactivity of the immunoblot and 
ImmunoCAP can be explained by their experimental charac-
teristics. As antigen-antibody balance can differ between im-
munoblot and the ImmunoCAP system, ImmunoCAP is known 
to be performed in antigen excess state.19 For this reason, IgE 
reactivity in the Hollister-Stier group (H1, H2, H4, H5) might 
be reduced only in immunoblots (Fig. 3A), and there was no 
significant change in ImmunoCAP test. 
Competition of IgG and IgE antibodies to 14 kDa allergen is 
thought to occur in IgE immunoblot analysis after SCIT. A re-
cent report showed that IgE binding affinity measured by the 
microarray system can be used as marker for immunotherapy 
instead of ImmunoCAP system measurement.20 This is con-
sistent with our experimental results. Further research with 
component allergen may be useful in the prediction of immu-
notherapy efficacy and diagnosis.21 
There are some limitations of the study. First, this study was 
retrospective; there were no data for symptom and medication 
scores. Allergic disease entities were different between the 
SCIT groups. More atopic dermatitis patients were recruited to 
the Tyrosine-S® group. Also, treatment duration was shortest 
in the Tyrosine-S® group (mean 12.8 months), compared with 
the Hollister-Stier® group (mean 15.2 months). Changes in IgE, 
IgG4, and blocking factor might not directly reflect real clini-
cal efficacy. Second, duration of the SCIT was short, 13 months 
on average. 
Patients were treated with mixed HDM reagents (D. farinae 
and D. pteronyssinus), and we only compared data to D. farinae 
related factors, as it is the dominant HDM species in Korea.22,23 
As both species have marked cross reactivity,24 it is expected 
that they will show a similar pattern. In addition to sIgE and 
sIgG4 levels to D. farinae, different sIgE responses to group 2 
major allergens were revealed in IgE immunoblotting (Der f 2) 
and ImmunoCAP (Der p 2) measurement. Der f 2 and Der p 2 
have well established cross reactivity25 and the group 2 aller-
gen of D. farinae (Der f 2) is commercially unavailable, and as 
such, we could only compare levels with Der p 2. 
In conclusion, there are differences in treatment outcomes of 
currently available HDM SCIT reagents. sIgG4, sIgE/IgG4 ra-
tio, and blocking factor indices vary according to the products. 
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